Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 8/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 6/20 | 0.40 |
| ▸ | AURKA | O14965 | 5/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12303615 | 0.85 | KCNH2 (0.51) | RAB9ARPS6KB1AURKAKCNH2CD38 | |
| SCHEMBL12303339 | 0.78 | HDAC3 (0.46) | MAPK10MAPK8 | |
| SCHEMBL11991519 | 0.72 | KMT2A (0.35) | MAPK10MAPK8PTGER4 | |
| SCHEMBL11991535 | 0.72 | KMT2A (0.35) | MAPK10MAPK8 | |
| SCHEMBL11992594 | 0.71 | KMT2A (0.35) | MAPK10MAPK8 | |
| SCHEMBL12303335 | 0.69 | KCNH2 (0.74) | KCNH2 | |
| SCHEMBL11922579 | 0.69 | TDP1 (0.48) | KCNH2 | |
| SCHEMBL12303834 | 0.69 | KCNH2 (0.54) | KCNH2 | |
| SCHEMBL12303836 | 0.67 | KDM4E (0.48) | MAPK10RPS6KB1AURKAMAPK8AURKB | |
| SCHEMBL12946090 | 0.67 | DRD1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| WO-2011032277-A1 | QUINAZOLINONE DERIVATIVES AS VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | RAB9A 1527/4885MAPK10 3660/4885RPS6KB1 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.